Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.
Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, Mach MA, Sutrave G, Clancy LE, Bishop DC, Louie RHY, Cai C, Foox J, MacKay M, Sedlazeck FJ, Blombery P, Mason CE, Luciani F, Gottlieb DJ, Blyth E. Micklethwaite KP, et al. Among authors: street ja. Blood. 2021 Oct 21;138(16):1391-1405. doi: 10.1182/blood.2021010858. Blood. 2021. PMID: 33974080 Free PMC article. Clinical Trial.
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells.
Bishop DC, Clancy LE, Simms R, Burgess J, Mathew G, Moezzi L, Street JA, Sutrave G, Atkins E, McGuire HM, Gloss BS, Lee K, Jiang W, Maddock K, McCaughan G, Avdic S, Antonenas V, O'Brien TA, Shaw PJ, Irving DO, Gottlieb DJ, Blyth E, Micklethwaite KP. Bishop DC, et al. Among authors: street ja. Blood. 2021 Oct 21;138(16):1504-1509. doi: 10.1182/blood.2021010813. Blood. 2021. PMID: 34010392 Free article. Clinical Trial. No abstract available.
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.
Gottlieb DJ, Sutrave G, Jiang W, Avdic S, Street JA, Simms R, Clancy LE, Antonenas V, Gloss BS, Bateman C, Bishop DC, Micklethwaite KP, Blyth E. Gottlieb DJ, et al. Among authors: street ja. Am J Hematol. 2023 Jan;98(1):159-165. doi: 10.1002/ajh.26594. Epub 2022 May 20. Am J Hematol. 2023. PMID: 35560045 Free PMC article.
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, McGuire HM, Patrick E, Chan AS, McCaughan G, Myers N, Micklethwaite KP, Antonenas V, Selim AG, Ritchie D, Bateman CM, Shaw PJ, Blyth E, Gottlieb DJ. Jiang W, et al. Blood Adv. 2022 Sep 13;6(17):4949-4966. doi: 10.1182/bloodadvances.2022007103. Blood Adv. 2022. PMID: 35819448 Free PMC article.
Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study).
Jiang W, Avdic S, Lee KH, Street J, Castellano-González G, Simms R, Clancy LE, Blennerhassett R, Patrick E, Chan AS, McGuire HM, Myers N, Gloss BS, Gabriel M, Bateman CM, Micklethwaite K, Gottlieb DJ, Blyth E. Jiang W, et al. Leukemia. 2023 Nov;37(11):2330-2333. doi: 10.1038/s41375-023-02033-5. Epub 2023 Sep 15. Leukemia. 2023. PMID: 37714926 No abstract available.
30 results